MASS - 908 Devices Inc.
TTM Technologies (NASDAQ: TTMI - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both technology companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability. Analyst Ratings This is a breakdown of recent
908 Devices Inc. (NASDAQ: MASS - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday. The company traded as high as $13.30 and last traded at $12.8250, with a volume of 39458 shares trading hands. The stock had previously closed at $12.80. Wall Street Analyst Weigh In Several brokerages have issued
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) ("Masivo" or the "Company") is pleased to report encouraging analytical results from Drill Hole CC-26-001, the first drill hole completed as part of the Company's current exploration program at its Cerro Colorado Project in Sonora, Mexico. CC-26-001 intersected a broad polymetallic mineralized system, including 32.50 metres from 226.30 to 258.80 metres averaging 0.271% Zn, 7.0 g/t Ag, 0.141% Pb, 0.025% Cu and 0.01 g/t Au.
IPG Photonics (NASDAQ: IPGP - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Profitability This table compares IPG Photonics and 908
908 Devices Inc. (NASDAQ: MASS - Get Free Report) SVP John Kenneweg sold 5,257 shares of the business's stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $10.22, for a total transaction of $53,726.54. Following the sale, the senior vice president owned 57,784 shares of the
908 Devices Inc. (NASDAQ: MASS - Get Free Report) SVP John Kenneweg sold 21,399 shares of 908 Devices stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $10.11, for a total transaction of $216,343.89. Following the completion of the sale, the senior vice president directly owned 57,784 shares
Plexus (NASDAQ: PLXS - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. Analyst Ratings This is a breakdown of current ratings
BlackRock Inc. acquired a new stake in shares of 908 Devices Inc. (NASDAQ: MASS) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,944,236 shares of the company's stock, valued at approximately $16,915,000. BlackRock Inc. owned approximately 5.14% of
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
908 Devices (NASDAQ: MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said the company has spent the past 18 months reshaping its operations around portable tools
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.